Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP49: Efficacy of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in ulcerative colitis: results from the open-label extension study TURANDOT IIECCO'19 Copenhagen
Year: 2019
Authors: Walter Reinisch
Ulcerative colitis
Files: 1
DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitisECCO'19 Copenhagen
Year: 2019
Authors: Walter Reinisch
Ulcerative colitis, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers
Files: 1
DOP52: Reduction in inflammatory biomarkers in a phase 2 study of mirikizumab in patients with moderately-to-severely active ulcerative colitisECCO'19 Copenhagen
Year: 2019
Authors: William J. Sandborn
Ulcerative colitis, Commercial
Files: 1
DOP53: Clinical, Endoscopic, Histologic and Biomarker Activity Following Treatment with the Gut-Selective, pan-JAK Inhibitor TD-1473 in Moderately-to-Severely Active Ulcerative ColitisECCO'19 Copenhagen
Year: 2019
Authors: Julián Panés
JAK inhibitors
Files: 1
DOP54: Efficacy and safety of ustekinumab through week 16 in patients with moderate to severe ulcerative colitis randomised to ustekinumab: Results from the UNIFI induction trialECCO'19 Copenhagen
Year: 2019
Authors: Silvio Danese
Ulcerative colitis, Ustekinumab
Files: 1
DOP55: ZNF133 is associated with infliximab responsiveness in patients with inflammatory bowel diseases using whole-exome sequencingECCO'19 Copenhagen
Year: 2019
Authors: Eun Suk Jung
Anti-TNF agents, Infliximab, Pharmacogenetics
Files: 1
DOP57: Monitoring response to anti-TNF therapy in ulcerative colitis patients by gastrointestinal ultrasound: sub-analysis from TRUST UCECCO'19 Copenhagen
Year: 2019
Authors: Christian Maaser
Ulcerative colitis, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Mucosal healing, Ultrasound, Adalimumab, Anti-TNF agents, Golimumab, Infliximab, Real world data, Mucosal healing
Files: 1
DOP58: IDeaL – a multi-center prospective Infliximab Dose to Level pharmacokinetic study during induction in pediatric Crohn’s diseaseECCO'19 Copenhagen
Year: 2019
Authors: Geraldine H. Huynh
Anti TNF drug levels, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Therapeutic drug monitoring, Infliximab, Pharmacokinetics, Paediatric, Investigator-led
Files: 1
DOP59: Proactive Infliximab Drug Monitoring Is Superior To Conventional Management In Inflammatory Bowel DiseaseECCO'19 Copenhagen
Year: 2019
Authors: Samuel Raimundo Fernandes
Anti TNF drug levels, Mucosal healing, Therapeutic drug monitoring, Infliximab
Files: 1
DOP61: A nationwide cohort study of colectomy rates for ulcerative colitis during the introduction of biologic therapyECCO'19 Copenhagen
Year: 2019
Authors: Jonathan Segal
Epidemiology, Natural history, Ulcerative colitis, Colectomy, Anti-TNF agents, Infliximab, Acute Severe Colitis
Files: 1
DOP62: A Novel Formulation of CT-P13 (Infliximab Biosimilar) for Subcutaneous Administration: 1-Year Result from a Phase I Open-label Randomised Controlled Trial in Patients with Active Crohn’s DiseaseECCO'19 Copenhagen
Year: 2019
Authors: Walter Reinisch
Outcome measures, Mucosal healing, Infliximab, Pharmacokinetics
Files: 1
DOP63: Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort studyECCO'19 Copenhagen
Year: 2019
Authors: Guillaume Pineton de Chambrun
Natural history, Crohn’s disease, Montreal Classification, MRI, Adalimumab, Anti-TNF agents, Penetrating disease, Abscess, Outcome measures
Files: 1
DOP64: Minimal additional benefits in adding fecal hemoglobin to fecal calprotectin in predicting endoscopic disease activity in patients with inflammatory bowel diseaseECCO'19 Copenhagen
Year: 2019
Authors: Lung-Yi Mak
Crohn’s disease, Ulcerative colitis, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers
Files: 1
DOP65: The association of fecal calprotectin level and combined mucosal and transmural healing in patients with Crohn's diseaseECCO'19 Copenhagen
Year: 2019
Authors: Soomin Noh
Calprotectin and other faecal biomarkers, Crohn’s disease
Files: 1
DOP66: Surveillance colonoscopies in Ulcerative Colitis: Does it make a difference?ECCO'19 Copenhagen
Year: 2019
Authors: Narula Neeraj
Colonoscopic surveillance, colonoscopy, Colonoscopy, UC colorectal cancer surveillance, IBD-associated cancer, Colorectal cancer
Files: 1
DOP67: Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histologic inflammation in patients with inflammatory bowel diseaseECCO'19 Copenhagen
Year: 2019
Authors: Entcho Klenske
Crohn’s disease, Ulcerative colitis, colonoscopy, Mucosal healing, Chromoendoscopy, Colonoscopy, Mucosal healing, Disease activity indices, Mucosal healing
Files: 1
DOP70: An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's diseaseECCO'19 Copenhagen
Year: 2019
Authors: Bram Verstockt
Treat to target, Ustekinumab
Files: 1
DOP71: Effects of ustekinumab induction therapy on endoscopic and histologic healing in the UNIFI phase 3 study in ulcerative colitisECCO'19 Copenhagen
Year: 2019
Authors: Katherine Li
Histology, Ulcerative colitis, Mucosal healing, Ustekinumab, Mucosal healing, Mucosal healing
Files: 1
DOP72: Increased risk of advanced neoplasia in inflammatory bowel disease patients with recurrent low-grade dysplasiaECCO'19 Copenhagen
Year: 2019
Authors: Michiel de Jong
Crohn’s disease, Ulcerative colitis, Dysplasia, Dysplasia, Colorectal cancer
Files: 1
DOP73: Treatment of perianal fistulas in Crohn’s disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): a randomised controlled trialECCO'19 Copenhagen
Year: 2019
Authors: Karin Wasmann
Disease activity Indices, Patient reported outcomes, Quality of life (IBDQ), MDT, 5-ASA, Adalimumab, Anti-TNF agents, Infliximab, Thiopurines (AZA / MP), Perianal disease, Perianal fistulae, Abscess, Perianal disease, Adherence to therapy, Sexuality, Real world data, Patient reported outcomes
Files: 1